Stay updated with breaking news from Pharma Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NeoGenomics (NASDAQ:NEO – Get Rating) updated its FY 2023 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of -$0.38–$0.32 for the period, compared to the consensus estimate of -$0.44. The company issued revenue guidance of $545.00 million-$555.00 million, compared to the consensus revenue estimate of $549.97 million. Analyst Upgrades and Downgrades […]
NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) has been given a consensus rating of “Moderate Buy” by the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eight have issued a buy recommendation on the company. The […]
NeoGenomics (NASDAQ:NEO – Get Rating) had its price objective trimmed by Bank of America from $18.00 to $17.00 in a research report report published on Tuesday, The Fly reports. The brokerage currently has a neutral rating on the medical research company’s stock. Other equities analysts have also issued research reports about the stock. Raymond James […]
The following Management's Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information necessary to understand our audited consolidated financial... | April 12, 2023
NeoGenomics (NASDAQ:NEO – Get Rating) had its price target decreased by stock analysts at Bank of America from $18.00 to $17.00 in a research note issued on Tuesday, The Fly reports. Bank of America‘s price objective would indicate a potential upside of 11.48% from the stock’s previous close. Other equities analysts have also issued research […]